ESMO 2024: Imfinzi to be practice changing in perioperative bladder cancer setting
The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.
Themes
ESMO 2024: Tecentriq/Avastin’s prospects as the first HCC adjuvant therapy fade
Alio starts trial to expand label for remote monitoring device
EASD 2024: Mazdutide improves cardiometabolic function in overweight patients
Testosterone could influence men’s immune response to Covid-19
AstraZeneca eyes up transition to eco-friendly inhaler propellant
As mpox spreads, ‘national governments have a moral responsibility to help’
IN8bio cuts staff and pipeline to focus on AML cell therapy
